Bank of New York Mellon Corp raised its position in Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) by 0.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 541,551 shares of the biopharmaceutical company’s stock after buying an additional 259 shares during the period. Bank of New York Mellon Corp owned 0.40% of Achillion Pharmaceuticals worth $4,224,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Achillion Pharmaceuticals during the first quarter worth about $101,000. Fox Run Management L.L.C. purchased a new stake in shares of Achillion Pharmaceuticals during the second quarter worth about $105,000. Legal & General Group Plc raised its stake in shares of Achillion Pharmaceuticals by 15.7% in the first quarter. Legal & General Group Plc now owns 18,010 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 2,443 shares in the last quarter. HBK Investments L P purchased a new stake in shares of Achillion Pharmaceuticals during the first quarter worth about $455,000. Finally, Royal Bank of Canada raised its stake in shares of Achillion Pharmaceuticals by 29.3% in the first quarter. Royal Bank of Canada now owns 64,385 shares of the biopharmaceutical company’s stock worth $497,000 after buying an additional 14,584 shares in the last quarter. 79.43% of the stock is currently owned by institutional investors.
Shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) traded down 4.03% on Monday, hitting $8.34. The stock had a trading volume of 2,068,465 shares. The company has a 50-day moving average of $8.48 and a 200 day moving average of $8.41. Achillion Pharmaceuticals Inc. has a 52 week low of $5.57 and a 52 week high of $10.95. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of 170.20 and a beta of 2.21.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. During the same period in the prior year, the business posted ($0.25) EPS. On average, equities research analysts predict that Achillion Pharmaceuticals Inc. will post ($0.61) EPS for the current year.
A number of equities research analysts recently issued reports on the company. Robert W. Baird reissued an “outperform” rating and issued a $10.00 target price on shares of Achillion Pharmaceuticals in a research report on Monday, June 6th. Leerink Swann reissued a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Sunday, June 12th. Jefferies Group reissued a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Tuesday, August 9th. Chardan Capital assumed coverage on Achillion Pharmaceuticals in a research report on Thursday, July 14th. They issued a “sell” rating and a $4.00 target price on the stock. Finally, Zacks Investment Research lowered Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 17th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. Achillion Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $10.70.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.
Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals Inc. (NASDAQ:ACHN).
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.